1-2 of 2
Eric Bischoff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer

Guangzhou Han, Eunmi Hwang, Fanching Lin, Renee Clift, Daniel Kim, Matt Guest, Eric Bischoff, Susan Moran, Gary Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1434–1443.
https://doi.org/10.1158/1535-7163.MCT-23-0029
Published: 01 December 2023
View article titled, RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer
Open the PDF for RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A133: A novel class of selective estrogen receptor degraders regresses tumors in preclinical models of endocrine-resistant breast cancer.

Beatrice Darimont, Steven Govek, James Joseph, Katherine Grillot, Eric Bischoff, Anna Aparicio, Celine Bonnefous, Karensa Douglas, Jackline Julien, Mehmet Kahraman, Joshua Kaufman, Andiliy Lai, Kyoung-Jin Lee, Nhin Lu, Johnny Nagasawa, Rene Prudente, Jing Qian, John Sensintaffar, Gang Shao, Richard Heyman, Peter Rix, Nicholas Smith, Jeffrey Hager
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A133.
https://doi.org/10.1158/1535-7163.TARG-11-A133
Published: 12 November 2011
View article titled, Abstract A133: A novel class of selective estrogen receptor degraders regresses tumors in preclinical models of endocrine-resistant breast cancer.